

ÜBERSICHTSARBEIT

Karger Kompass Pneumol 2018;6:77–89 • DOI: 10.1159/000487985
Übersetzung aus Respiration 2017;94:467–485 • DOI: 10.1159/000485106

Supplemental Material

Literatur

- 1 Urban T, Lazor R, Lacronique J, Murris M, Labrune S, Valeyre D, Cordier JF: Pulmonary lymphangioleiomyomatosis: a study of 69 patients. *Groupe d'Etudes et de Recherche sur les Maladies «Orphelines» Pulmonaires (GERM«O»P)*. Medicine (Baltimore) 1999;78:321–337.
- 2 Johnson SR, Tattersfield AE: Clinical experience of lymphangioleiomyomatosis in the UK. *Thorax* 2000;55:1052–1057.
- 3 Harknett EC, Chang WYC, Byrnes S, Johnson J, Lazor R, Cohen MM, Gray B, Geiling S, Telford H, Tattersfield AE, Hubbard RB, Johnson SR: Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. *QJM* 2011;104:971–979.
- 4 Curatolo P, Bombardieri R, Jozwiak S: Tuberous sclerosis. *Lancet* 2008; 372:657–668.
- 5 Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group: Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013;49:243–254.
- 6 Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group: Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatr Neurol* 2013;49:255–265.
- 7 Seibert D, Hong CH, Takeuchi F, Olsen C, Hathaway O, Moss J, Darling TN: Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences. *Ann Intern Med* 2011;154:806–813.
- 8 Johnson SR, Taveira-DaSilva AM, Moss J: Lymphangioleiomyomatosis. *Clin Chest Med* 2016;37:389–403.
- 9 Lazor R, Valeyre D, Lacronique J, Wallaert B, Urban T, Cordier JF; Groupe d'Etudes et de Recherche sur les Maladies «Orphelines» Pulmonaires: Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. *Respir Med* 2004;98:536–541.
- 10 Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Rafkin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL; NHLBI LAM Registry Group: The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. *Am J Respir Crit Care Med* 2006;173:105–111.
- 11 Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J: Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. *Am J Respir Crit Care Med* 2001;164:1072–1076.
- 12 Johnson SR, Whale CI, Hubbard RB, Lewis SA, Tattersfield AE: Survival and disease progression in UK patients with lymphangioleiomyomatosis. *Thorax* 2004;59:800–803.
- 13 Oprescu N, McCormack FX, Byrnes S, Kinder BW: Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. *Lung* 2013;191:35–42.
- 14 Taveira-DaSilva AM, Hathaway OM, Sach-dev V, Shizukuda Y, Birdsell CW, Moss J: Pulmonary artery pressure in lymphangioleiomyomatosis: an echo-cardiographic study. *Chest* 2007;132:1573–1578.
- 15 Freitas CSG, Baldi BG, Jardim C, Araujo MS, Sobral JB, Heiden GI, Kairalla RA, Souza R, Carvalho CRR: Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. *Orphanet J Rare Dis* 2017;12:74.
- 16 Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J: Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. *Chest* 2009;135:1293–1300.
- 17 Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, Franz DN, McCormack FX, Young LR: Lymphangioleiomyomatosis screening in women with tuberous sclerosis. *Chest* 2013;144:578–585.
- 18 Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP

- 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group: Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. *Lancet Respir Med* 2013;1:445–452.
- 19 McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al; ATS/JTS Committee on Lymphangioleiomyomatosis: Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. *Am J Respir Crit Care Med* 2016; 194:748–761.
- 20 Yeoh ZW, Navaratnam V, Bhatt R, McCafferty I, Hubbard RB, Johnson SR: Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance. *Orphanet J Rare Dis* 2014;9:151.
- 21 Taveira-DaSilva AM, Jones AM, Julian-Williams P, Yao J, Stylianou M, Moss J: Severity and outcome of cystic lung disease in women with tuberous sclerosis complex. *Eur Respir J* 2015; 45: 171–180.
- 22 Aubry MC, Myers JL, Ryu JH, Henske EP, Logginidou H, Jalal SM, Tazelaar HD: Pulmonary lymphangioleiomyomatosis in a man. *Am J Respir Crit Care Med* 2000; 162:749–752.
- 23 Schiavina M, Di Scioscio V, Contini P, Cavazza A, Fabiani A, Barberis M, Bini A, Altimari A, Cooke RM, Grigioni WF, D'Errico-Grigioni A: Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. *Am J Respir Crit Care Med* 2007;176:96–98.
- 24 Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, Zonnenberg BA, Prokop M: Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. *Clin Radiol* 2011;66:625–628.
- 25 Ryu JH, Sykes AM, Lee AS, Burger CD: Cystic lung disease is not uncommon in men with tuberous sclerosis complex. *Respir Med* 2012;106:1586–1590.
- 26 Moss J, DeCastro R, Patronas NJ, Taveira-DaSilva A: Meningiomas in lymphangioleiomyomatosis. *JAMA* 2001;286:1879–1881.
- 27 Cottin V, Vukusic S, Jouanneau E, Lazor R, Cordier JF: Should patients with lymphangioleiomyomatosis undergo screening for meningioma? *Eur Respir J* 2004; 24:888–889.
- 28 McCormack FX, Travis WD, Colby TV, Henske EP, Moss J: Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. *Am J Respir Crit Care Med* 2012;186:1210–1212.
- 29 Thway K, Fisher C: PEComa: morphology and genetics of a complex tumor family. *Ann Diagn Pathol* 2015;19:359–368.
- 30 Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J: Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. *Am J Respir Cell Mol Biol* 1999;21:327–336.
- 31 Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD: Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). *Hum Pathol* 1997;28: 1071–1078.
- 32 Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y: Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. *Lymphat Res Biol* 2006;4:143–152.
- 33 Issaka RB, Oommen S, Gupta SK, Liu G, Myers JL, Ryu JH, Vlahakis NE: Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. *Am J Pathol* 2009;175:1410–1420.
- 34 Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP: Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. *Am J Hum Genet* 1998;62:810–815.
- 35 Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. *Proc Natl Acad Sci USA* 2000;97:6085–6090.
- 36 Barnes EA, Kenerson HL, Mak BC, Yeung RS: The loss of tuberin promotes cell invasion through the β-catenin pathway. *Am J Respir Cell Mol Biol* 2010;43:617–627.
- 37 Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF: β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. *Am J Clin Pathol* 2011;135:776–782.
- 38 Pacheco-Rodriguez G, Steagall WK, Crooks DM, Stevens LA, Hashimoto H, Li S, Wang JA, Darling TN, Moss J: TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. *Cancer Res* 2007;67:10573–10581.
- 39 Li S, Takeuchi F, Wang JA, Fuller C, Pacheco-Rodriguez G, Moss J, Darling TN: MCP-1 overexpressed in tuberous sclerosis lesions acts as a

- paracrine factor for tumor development. *J Exp Med* 2005;202:617-624.
- 40 Pacheco-Rodriguez G, Kumaki F, Steagall WK, Zhang Y, Ikeda Y, Lin JP, Billings EM, Moss J: Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. *J Immunol* 2009;182: 1270-1277.
- 41 Mitani K, Kumasaki T, Takemura H, Hayashi T, Gunji Y, Kunogi M, Akiyoshi T, Takahashi K, Suda K, Seyama K: Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis. *Acta Cytol* 2009;53:402-409.
- 42 Seaman DM, Meyer CA, Gilman MD, McCormack FX: Diffuse cystic lung disease at high-resolution CT. *AJR Am J Roentgenol* 2011;196: 1305-1311.
- 43 Toro JR, Pautler SE, Stewart L, Glenn GM, Weinreich M, Toure O, Wei MH, Schmidt LS, Davis L, Zbar B, Choyke P, Steinberg SM, Nguyen DM, Linehan WM: Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. *Am J Respir Crit Care Med* 2007; 175:1044-1053.
- 44 Tobino K, Gunji Y, Kurihara M, Kunogi M, Koike K, Tomiyama N, Johkoh T, Kodama Y, Iwakami S, Kikkawa M, Takahashi K, Seyama K: Characteristics of pulmonary cysts in Birt-Hogg-Dubé syndrome: thin-section CT findings of the chest in 12 patients. *Eur J Radiol* 2011;77:403-409.
- 45 Castoldi MC, Verrioli A, De Juli E, Vanzulli A: Pulmonary Langerhans cell histio-cytosis: the many faces of presentation at initial CT scan. *Insights Imaging* 2014;5:483-492.
- 46 Colombat M, Stern M, Groussard O, Droz D, Brauner M, Valeyre D, Mal H, Taillé C, Monnet I, Fournier M, Herson S, Danel C: Pulmonary cystic disorder related to light chain deposition disease. *Am J Respir Crit Care Med* 2006; 173:777-780.
- 47 Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX: Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. *Am J Respir Crit Care Med* 2001;164:661-668.
- 48 Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J: Lymphangioleiomyomatosis: abdominopelvic CT and US findings. *Radiology* 2000; 216:147-153.
- 49 Avila NA, Dwyer AJ, Moss J: Imaging features of lymphangioleiomyomatosis: diagnostic pitfalls. *AJR Am J Roentgenol* 2011;196:982-986.
- 50 Avila NA, Bechtle J, Dwyer AJ, Ferrans VJ, Moss J: Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. *Radiology* 2001;221:415-421.
- 51 Taveira-DaSilva AM, Jones AM, Julien-Williams P, Shawker T, Glasgow CG, Stylianou M, Moss J: Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis. *Chest* 2015;148:1027-1033.
- 52 European Chromosome 16 Tuberous Sclerosis Consortium: Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 1993;75:1305-1315.
- 53 van Slegtenhorst M, de Hoogt R, Hermans C, Nellist M, Janssen B, Verhoef S, et al: Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science* 1997;277:805-808.
- 54 Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. *Am J Hum Genet* 2001;68:64-80.
- 55 Knudson AG: Two genetic hits (more or less) to cancer. *Nat Rev Cancer* 2001;1:157-162.
- 56 Montagne J, Radimerski T, Thomas G: Insulin signaling: lessons from the *Drosophila* tuberous sclerosis complex, a tumor suppressor. *Sci STKE* 2001;2001:pe36.
- 57 Henske EP, McCormack FX: Lymphangioleiomyomatosis - a wolf in sheep's clothing. *J Clin Invest* 2012;122:3807-3816.
- 58 Krymskaya VP, McCormack FX: Lymphangioleiomyomatosis: a monogenic model of malignancy. *Annu Rev Med* 2017;68:69-83.
- 59 Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP: The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis. *Oncogene* 2009;28:1594-1604.
- 60 Tsun ZY, Bar-Peled L, Chantranupong L, Zoncu R, Wang T, Kim C, Spooner E, Sabatini DM: The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1. *Mol Cell* 2013;52:495-505.
- 61 Yano S: Exacerbation of pulmonary lymphangioleiomyomatosis by exo-genous oestrogen used for infertility treatment. *Thorax* 2002;57:1085-1086.
- 62 Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J: Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. *Chest* 2004;126:1867-1874.

- 63 Yu J, Astrinidis A, Howard S, Henske EP: Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. *Am J Physiol Lung Cell Mol Physiol* 2004;286:L694–L700.
- 64 Glassberg MK, Elliot SJ, Fritz J, Cata-nuto P, Potier M, Donahue R, Stetler-Stevenson W, Karl M: Activation of the estrogen receptor contributes to the progression of pulmonary lymphangio-leiomomatosis via matrix metallo-proteinase-induced cell invasiveness. *J Clin Endocrinol Metab* 2008; 93:1625–1633.
- 65 Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, Astrinidis A, Wang C, Hernandez-Cuevas L, See-holzer LF, Nicolas E, Hensley H, Jordan VC, Walker CL, Henske EP: Estrogen promotes the survival and pulmonary metastasis of tuber-null cells. *Proc Natl Acad Sci USA* 2009;106:2635–2640.
- 66 Hayashi T, Kumasaka T, Mitani K, Terao Y, Watanabe M, Oide T, Nakanishi Y, Hebisawa A, Konno R, Takahashi K, Yao T, Seyama K: Prevalence of uterine and adnexal involvement in pulmonary lymphangioleiomyomatosis: a clinic-pathologic study of 10 patients. *Am J Surg Pathol* 2011;35:1776–1785.
- 67 Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, Hayashi S, Minami M, Uekusa T, Fukuchi Y, Suda K: Lymphangiogenesis in lymphangioleio-myomatosis: its implication in the progression of lymphangioleiomyo-matosis. *Am J Surg Pathol* 2004;28:1007–1016.
- 68 Bittmann I, Rolf B, Amann G, Löhrs U: Recurrence of lymphangioleiomatosis after single lung transplantation: new insights into pathogenesis. *Hum Pathol* 2003; 34:95–98.
- 69 Karbowniczek M, Astrinidis A, Bal-sara BR, Testa JR, Liim JH, Colby TV, McCormack FX, Henske EP: Recurrent lymphangioleiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. *Am J Respir Crit Care Med* 2003;167: 76–982.
- 70 Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J: Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. *Proc Natl Acad Sci USA* 2004;101:17462–17467.
- 71 Cai X, Pacheco-Rodriguez G, Fan QY, Haughey M, Samsel L, El-Che-maly S, Wu HP, McCoy JP, Steagall WK, Lin JP, Darling TN, Moss J: Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. *Am J Respir Crit Care Med* 2010; 182:1410–1418.
- 72 Steagall WK, Zhang L, Cai X, Pacheco-Rodriguez G, Moss J: Genetic heterogeneity of circulating cells from patients with lymphangioleiomyomatosis with and without lung transplantation. *Am J Respir Crit Care Med* 2015; 191:854–856.
- 73 Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ: Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. *Arch Pathol Lab Med* 2000; 124:267–275.
- 74 Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, Bonetti F, Kingswood C; Review Panel of the ERS LAM Task Force: European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. *Eur Respir J* 2010;35:14–26.
- 75 Avila NA, Dwyer AJ, Rabel A, Dar-ling T, Hong CH, Moss J: CT of sclero-tic bone lesions: imaging fea-tures differentiating tuberous scler-o-sis complex with lymphangioleiomyomatosis from sporadic lymphangioleiomyomatosis. *Radiol-ogy* 2010;254:851–857.
- 76 Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr: TSC2 reg-u-lates VEGF through mTOR-de-pendent and -independent path-ways. *Cancer Cell* 2003;4:147–158.
- 77 Young LR, Inoue Y, McCormack FX: Diagnostic potential of serum VEGF-D for lymphangioleiomyo-matosis. *N Engl J Med* 2008; 358:199–200.
- 78 Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX: Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. *Chest* 2010;138: 674–681.
- 79 Chang WY, Cane JL, Blakey JD, Ku-mararan M, Pointon KS, Johnson SR: Clinical utility of diagnostic guide-lines and putative biomarkers in lymphangioleiomyomatosis. *Respir Res* 2012;13:34.
- 80 Harari S, Torre O, Cassandro R, Taveira-DaSilva AM, Moss J: Bron-choscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. *Respir Med* 2012;106:1286–1292.
- 81 Meraj R, Wikenheiser-Brokamp KA, Young LR, Byrnes S, McCormack FX: Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. *Front Med* 2012;6:395–405.
- 82 Koba T, Arai T, Kitaichi M, Kasai T, Hirose M, Tachibana K, Sugimoto C, Akira M, Hayashi S, Inoue Y: Ef-ficacy and safety of transbronchial lung biopsy for the diagnosis of lymphangioleiomyomatosis: a re-port of 24 consecutive patients.

- Respirology 2017, Epub ahead of print.
- 83 Fruchter O, Fridel L, El Raouf BA, Abdel-Rahman N, Rosengarten D, Kramer MR: Histological diagnosis of interstitial lung diseases by cryo-transbronchial biopsy. *Respirology* 2014;19:683–688.
- 84 Radzikowska E, Jaguś P, Sobiecka M, Chorostowska-Wynimko J, Wiatr E, Kuś J, Roszkowski-Śliż K: Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymph-angioleiomyomatosis. *Respir Med* 2015;109: 1469–1475.
- 85 Taveira-DaSilva AM, Jones AM, Julian-Williams P, Stylianou M, Moss J: Long-term effect of sirolimus on serum vascular endothelial growth factor D levels in patients with lymphangioleiomyomatosis. *Chest* 2017, Epub ahead of print.
- 86 Araujo MS, Baldi BG, Freitas CS, Albuquerque AL, Marques da Silva CC, Kairalla RA, Carvalho CR, Carvalho CR: Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. *Eur Respir J* 2016;47:1452–
- 87 Taveira-DaSilva AM, Steagall WK, Rabel A, Hathaway O, Harari S, Cassandro R, Stylianou M, Moss J: Reversible airflow obstruction in lymphangioleiomyomatosis. *Chest* 2009;136:1596–1603.
- 88 Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J: Bone mineral density in lymphangioleiomyomatosis. *Am J Respir Crit Care Med* 2005;171:61–67.
- 89 Pollock-BarZiv S, Cohen MM, Downey GP, Johnson SR, Sullivan E, McCormack FX: Air travel in women with lymphangioleiomyomatosis. *Thorax* 2007;62:176–180.
- 90 Taveira-DaSilva AM, Burstein D, Hathaway OM, Fontana JR, Go-chuico BR, Avila NA, Moss J: Pneu-
- mothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. *Chest* 2009;136:665–670.
- 91 Cohen MM, Freyer AM, Johnson SR: Pregnancy experiences among women with lymphangioleiomyomatosis. *Respir Med* 2009; 103:766–772.
- 92 Almoosa KF, Ryu JH, Mendez J, Huggins JT, Young LR, Sullivan EJ, Maurer J, McCormack FX, Sahn SA: Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. *Chest* 2006;129: 1274–1281.
- 93 Kurihara M, Mizobuchi T, Kataoka H, Sato T, Kumakura T, Ebana H, Yamanaka S, Endo R, Miyashiro S, Shinya N, Seyama K: A total pleural covering for lymphangioleiomyomatosis prevents pneumothorax recurrence. *PLoS One* 2016; 11:e0163637.
- 94 Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. *N Engl J Med* 2008;358:140–151.
- 95 Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J: Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. *Ann Intern Med* 2011; 154:797–805.
- 96 Neurohr C, Hoffmann AL, Huppmann P, Herrera VA, Ihle F, Leuschner S, von Wulffen W, Meis T, Baezner C, Leuchte H, Baumgartner R, Zimmermann G, Behr J: Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? *Respir Res* 2011;12:66.
- 97 McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC: Efficacy and safety of sirolimus in lymphangioleiomyomatosis. *N Engl J Med* 2011;364:1595–1606.
- 98 Takada T, Mikami A, Kitamura N, Seyama K, Inoue Y, Nagai K, Suzuki M, Moriyama H, Akasaka K, Tazawa R, Hirai T, Mishima M, Hayashida M, Hirose M, Sugimoto C, Arai T, Hattori N, Watanabe K, Tamada T, Yoshizawa H, Akazawa K, Tanaka T, Yagi K, Young LR, McCormack FX, Nakata K: Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis. *Ann Am Thorac Soc* 2016;13:1912–1922.
- 99 Bee J, Fuller S, Miller S, Johnson SR: Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. *Thorax* 2017, Epub ahead of print.
- 100 Ando K, Kurihara M, Kataoka H, Ueyama M, Togo S, Sato T, Doi T, Iwakami S, Takahashi K, Seyama K, Mikami M: Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. *Respir Investig* 2013;51:175–183.
- 101 Goldberg HJ, Harari S, Cottin V, Rosas IO, Peters E, Biswal S, Cheng Y, Khindri S, Kovarik JM, Ma S, McCormack FX, Henske EP: Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. *Eur Respir J* 2015;46:783–794.
- 102 Johnson SR, Tattersfield AE: Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone

- treatment. *Am J Respir Crit Care Med* 1999;160:628–633.
- 103 Moses MA, Harper J, Folkman J: Doxy-cycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. *N Engl J Med* 2006;354:2621–2622.
- 104 Chang WY, Cane JL, Kumaran M, Lewis S, Tattersfield AE, Johnson SR: A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. *Eur Respir J* 2014;43:1114–1123.
- 105 El-Chemaly S, Taveira-DaSilva A, Goldberg HJ, Peters E, Haughey M, Bienfang D, Jones AM, Julien-Williams P, Cui Y, Villalba JA, Bagwe S, Maurer R, Rosas IO, Moss J, Henske EP: Sirolimus and autophagy inhibition in lymphangioleiomyomatosis: results of a phase I clinical trial. *Chest* 2017;151:1302–1310.
- 106 Lu C, Lee HS, Pappas GP, Dilling DF, Burger CD, Shifren A, Veeraraghavan S, Chapman JT, Parambil J, Ruoss SJ, Young LR, Hammes SR, Kopras EJ, Roads T, Krischer JP, McCormack FX; Trial of an Aromatase Inhibitor in Lymphangioleiomyomatosis Group: A phase II clinical trial of an aromatase inhibitor for postmenopausal women with lymphangioleiomyomatosis. *Ann Am Thorac Soc* 2017;14:919–928.
- 107 Boehler A, Speich R, Russi EW, Weder W: Lung transplantation for lymphangioleiomyomatosis. *N Engl J Med* 1996;335:1275–1280.
- 108 Kpodonu J, Massad MG, Chaer RA, Caines A, Evans A, Snow NJ, Geha AS: The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. *J Heart Lung Transplant* 2005; 24:1247–1253.
- 109 Reynaud-Gaubert M, Mornex JF, Mal H, Treilhaud M, Dromer C, Quétant S, Leroy-Ladurie F, Guillermain R, Philit F, Dauriat G, Grenet D, Stern M: Lung transplantation for lymphangioleiomyomatosis: the French experience. *Transplantation* 2008;86:515–520.
- 110 Benden C, Rea F, Behr J, Corris PA, Reynaud-Gaubert M, Stern M, Speich R, Boehler A: Lung transplantation for lymphangioleiomyomatosis: the Euro-pean experience. *J Heart Lung Transplant* 2009;28:1–7.
- 111 Ando K, Okada Y, Akiba M, Kondo T, Kawamura T, Okumura M, Chen F, Date H, Shiraishi T, Iwasaki A, Yamasaki N, Nagayasu T, Chida M, Inoue Y, Hirai T, Seyama K, Mishima M: Respiratory Failure Research Group of the Japanese Ministry of Health, Labour, and Welfare: Lung transplantation for lymphangioleiomyomatosis in Japan. *PLoS One* 2016;11:e0146749.
- 112 King-Biggs MB, Dunitz JM, Park SJ, Kay Savik S, Hertz MI: Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. *Transplantation* 2003;75:1437–1443.
- 113 Groetzner J, Kur F, Spelsberg F, Behr J, Frey L, Bittmann I, Vogeser M, Ueberfuhr P, Meiser B, Hatz R, Reichart B; Munich Lung Transplant Group: Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. *J Heart Lung Transplant* 2004;23:632–638.
- 114 Ohara T, Oto T, Miyoshi K, Tao H, Yamane M, Toyooka S, Okazaki M, Date H, Sano Y: Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. *Ann Thorac Surg* 2008; 86:e7–e8.
- 115 Morton JM, McLean C, Booth SS, Snell GI, Whitford HM: Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. *J Heart Lung Transplant* 2008;27:462–465.
- 116 Chen F, Omasa M, Kondo N, Fujinaga T, Shoji T, Sakai H, Bando T: Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. *Ann Thorac Surg* 2009;87:e6–e7.
- 117 Ito T, Suno M, Sakamoto K, Yoshihaki Y, Yamamoto K, Nakanishi R, Hirano Y, Irie M, Kuroasaki T, Otani S, Yamane M, Sugimoto S, Miyoshi K, Oto T: Therapeutic effect of sirolimus for lymphangioleiomyomatosis remaining in the abdominopelvic region after lung transplantation: a case report. *Transplant Proc* 2016;48:271–274.
- 118 Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR: Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. *N Engl J Med* 2008; 358:200–203.
- 119 Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K: Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. *PLoS One* 2017; 12:e0180939.
- 120 Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K: Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multi-centre, randomised, double-blind, placebo-controlled trial. *Lancet* 2013;381: 817–824.
- 121 Birt AR, Hogg GR, Dubé WJ: Hereditary multiple fibrofolliculomas

- with tricho-discomas and acrochordons. *Arch Dermatol* 1977; 113:1674–1677.
- 122 Hornstein OP, Knickenberg M: Perifollicular fibromatosis cutis with polyps of the colon – a cutaneo-intestinal syndrome sui generis. *Arch Dermatol Res* 1975; 253:161–175.
- 123 Binet O, Audefray D, Beltzer-Garely E, Gauchy O, Cesarin JP: Haber's syndrome. First French family (2 cases) (in French). *Ann Dermatol Venereol* 1986;113:43–50.
- 124 Roth JS, Rabinowitz AD, Benson M, Grossman ME: Bilateral renal cell carcinoma in the Birt-Hogg-Dubé syndrome. *J Am Acad Dermatol* 1993;29:1055–1056.
- 125 Chung JY, Ramos-Caro FA, Beers B, Ford MJ, Flowers F: Multiple lipomas, angioliomas, and parathyroid adenomas in a patient with Birt-Hogg-Dubé syndrome. *Int J Dermatol* 1996;35:365–367.
- 126 Toro JR, Glenn G, Duray P, Darling T, Weirich G, Zbar B, Linehan M, Turner ML: Birt-Hogg-Dubé syndrome: a novel marker of kidney neoplasia. *Arch Dermatol* 1999; 135:1195–1202.
- 127 Khoo SK, Bradley M, Wong FK, Hedblad MA, Nordenskjöld M, Teh BT: Birt-Hogg-Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromo-some 17p12-q11.2. *Oncogene* 2001;20: 5239–5242.
- 128 Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR, Turner ML, Duray P, Merino M, Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan WM, Zbar B: Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. *Am J Hum Genet* 2001;69:876–882.
- 129 Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke PL, Walther MM, Munroe D, Hill R, Maher E, Greenberg C, Lerman MI, Linehan WM, Zbar B, Schmidt LS: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. *Cancer Cell* 2002; 2:157–164.
- 130 Cottin V, Cordier JF, Khouatra C, Giraud S, Lazor R: Multiple cystic lung diseases; in Cottin V, Cordier JF, Richeldi L (eds): *Orphan Lung Diseases: A Clinical Guide to Rare Lung Disease*. Springer, 2015, pp 253–270.
- 131 Schmidt LS, Linehan WM: FLCN: the causative gene for Birt-Hogg-Dubé syndrome. *Gene* 2018;640: 28–42.
- 132 Schmidt LS, Nickerson ML, Warren MB, Glenn GM, Toro JR, Merino MJ, Turner ML, Choyke PL, Sharma N, Peterson J, Morrison P, Maher ER, Walther MM, Zbar B, Linehan WM: Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dubé syndrome. *Am J Hum Genet* 2005;76:1023–1033.
- 133 Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM: Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. *Proc Natl Acad Sci USA* 2009; 106:18722–18727.
- 134 Warren MB, Torres-Cabala CA, Turner ML, Merino MJ, Matrosova VY, Nickerson ML, Ma W, Linehan WM, Zbar B, Schmidt LS: Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues. *Mod Pathol* 2004; 17:98–1011.
- 135 Adley BP, Smith ND, Nayar R, Yang XJ: Birt-Hogg-Dubé syndrome: clinic-pathologic findings and genetic alterations. *Arch Pathol Lab Med* 2006;130:1865–1870.
- 136 Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B: Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. *Proc Natl Acad Sci USA* 2006;103:15552–15557.
- 137 Furuya M, Tanaka R, Koga S, Yatabe Y, Gotoda H, Takagi S, Hsu YH, Fujii T, Okada A, Kuroda N, Moritani S, Mizuno H, Nagashima Y, Nagaohama K, Hiroshima K, Yoshino I, Nomura F, Aoki I, Nakatani Y: Pulmonary cysts of Birt-Hogg-Dubé syndrome: a clinicopathologic and immunohistochemical study of 9 families. *Am J Surg Pathol* 2012; 36:589–600.
- 138 Goncharova EA, Goncharov DA, James ML, Atochina-Vasserman EN, Stepanova V, Hong SB, Li H, Gonzales L, Baba M, Linehan WM, Gow AJ, Margulies S, Guttentag S, Schmidt LS, Krymskaya VP: Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. *Cell Rep* 2014;7:412–423.
- 139 Khabibullin D, Medvetz DA, Pinilla M, Hariharan V, Li C, Hergrueter A, Laacho Contreras M, Zhang E, Parkhitko A, Yu JJ, Owen CA, Huang H, Baron RM, Henske EP: Folliculin regulates cell-cell adhesion, AMPK, and mTORC1 in a cell-type-specific manner in lung-derived cells. *Physiol Rep* 2014;2:e12107.
- 140 Dal Sasso AA, Belém LC, Zanetti G, Souza CA, Escuissato DL, Irion KL, Guimarães MD, Marchiori E: Birt-Hogg-Dubé syndrome. State-of-the-art review with emphasis on pulmonary involvement. *Respir Med* 2015;109:289–296.

- 141 Kennedy JC, Khabibullin D, Henske EP: Mechanisms of pulmonary cyst pathogenesis in Birt-Hogg-Dubé syndrome: the stretch hypothesis. *Semin Cell Dev Biol* 2016;52:47–52.
- 142 Graham RB, Nolasco M, Peterlin B, Garcia CK: Nonsense mutations in folliculin presenting as isolated familial spontaneous pneumothorax in adults. *Am J Respir Crit Care Med* 2005;172:39–44.
- 143 Painter JN, Tapanainen H, Somer M, Tukiainen P, Aittomäki K: A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax. *Am J Hum Genet* 2005;76:522–527.
- 144 Gunji Y, Akiyoshi T, Sato T, Kurihara M, Tominaga S, Takahashi K, Seyama K: Mutations of the Birt-Hogg-Dubé gene in patients with multiple lung cysts and recurrent pneumothorax. *J Med Genet* 2007; 44:588–593.
- 145 Fröhlich BA, Zeitz C, Mátyás G, Alkadhi H, Tuor C, Berger W, Russi EW: Novel mutations in the folliculin gene associated with spontaneous pneumo-thorax. *Eur Respir J* 2008;32:1316–1320.
- 146 Ren HZ, Zhu CC, Yang C, Chen SL, Xie J, Hou YY, Xu ZF, Wang DJ, Mu DK, Ma DH, Wang Y, Ye MH, Ye ZR, Chen BF, Wang CG, Lin J, Qiao D, Yi L: Mutation analysis of the FLCN gene in Chinese patients with sporadic and familial isolated primary spontaneous pneumothorax. *Clin Genet* 2008;74:178–183.
- 147 Kunogi M, Kurihara M, Ikegami TS, Kobayashi T, Shindo N, Kumashita T, Gunji Y, Kikkawa M, Iwakami S, Hino O, Takahashi K, Seyama K: Clinical and genetic spectrum of Birt-Hogg-Dubé syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature. *J Med Genet* 2010;47:281–287.
- 148 Gupta N, Seyama K, McCormack FX: Pulmonary manifestations of Birt-Hogg-Dubé syndrome. *Fam Cancer* 2013;12:387–396.
- 149 Menko FH, van Steensel MA, Giraad S, Friis-Hansen L, Richard S, Ungari S, Nordenskjöld M, Hansen TV, Solly J, Maher ER; European BHD Consortium: Birt-Hogg-Dubé syndrome: diagnosis and management. *Lancet Oncol* 2009;10: 1199–1206.
- 150 Murakami Y, Wataya-Kaneda M, Tanaka M, Takahashi A, Tsujimura A, Inoue K, Nonomura N, Katayama I: Two Japanese cases of Birt-Hogg-Dubé syndrome with pulmonary cysts, fibrofolliculomas, and renal cell carcinomas. *Case Rep Dermatol* 2014;6:20–28.
- 151 Furuya M, Yao M, Tanaka R, Nagashima Y, Kuroda N, Hasumi H, Baba M, Matsushima J, Nomura F, Nakatani Y: Genetic, epidemiologic and clinic-pathologic studies of Japanese Asian patients with Birt-Hogg-Dubé syndrome. *Clin Genet* 2016;90:403–412.
- 152 Park HJ, Park CH, Lee SE, Lee GD, Byun MK, Lee S, Lee KA, Kim TH, Kim SH, Yang SY, Kim HJ, Ahn CM: Birt-Hogg-Dubé syndrome prospectively detected by review of chest computed tomography scans. *PLoS One* 2017;12: e0170713.
- 153 Zbar B, Alvord WG, Glenn G, Turner M, Pavlovich CP, Schmidt L, Walther M, Choyke P, Weirich G, Hewitt SM, Duray P, Gabril F, Greenberg C, Merino MJ, Toro J, Linehan WM: Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. *Cancer Epidemiol Bio-markers Prev* 2002;11:393–400.
- 154 Tomassetti S, Carloni A, Chilosi M, Maffei A, Ungari S, Sverzellati N, Guaroli C, Casoni G, Romagnoli M, Guaroli C, Ravaglia C, Poletti V: Pulmonary features of Birt-Hogg-Dubé syndrome: cystic lesions and pulmonary histiocytoma. *Respir Med* 2011;105:768–774.
- 155 Cooley J, Lee YCG, Gupta N: Spontaneous pneumothorax in diffuse cystic lung diseases. *Curr Opin Pulm Med* 2017;23:323–333.
- 156 Houweling AC, Gijzen LM, Jonker MA, van Doorn MB, Oldenburg RA, van Spaendonck-Zwarts KY, Leter EM, van Os TA, van Grie-ken NC, Jaspars EH, de Jong MM, Bongers EM, Johannesma PC, Postmus PE, van Moorselaar RJ, van Waesberghe JH, Starink TM, van Steensel MA, Gille JJ, Menko FH: Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome: an analysis of 115 FLCN mutation carriers from 35 BHD families. *Br J Cancer* 2011;105:1912–1919.
- 157 Toro JR, Wei MH, Glenn GM, Weinreich M, Toure O, Vocke C, Turner M, Choyke P, Merino MJ, Pinto PA, Steinberg SM, Schmidt LS, Linehan WM: BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. *J Med Genet* 2008;45:321–331.
- 158 Johannesma PC, van de Beek I, van der Wel JW, Paul MA, Houweling AC, Jonker MA, van Waesberghe JH, Reinhard R, Starink TM, van Moorselaar RJ, Menko FH, Postmus PE: Risk of spontaneous pneumothorax due to air travel and diving in patients with Birt-Hogg-Dubé syndrome. *Springerplus* 2016;5: 1506.
- 159 Gupta N, Kopras EJ, Henske EP, James LE, El-Chemaly S, Veeraghavan S, Drake MG, McCormack FX: Spontaneous pneumothoraces in patients with Birt-Hogg-Dubé syndrome. *Ann Am Thorac Soc* 2017;14:706–713.
- 160 Postmus PE, Johannesma PC, Menko FH, Paul MA: In-flight pneumothorax: diagnosis may be

- missed because of symptom delay. Am J Respir Crit Care Med 2014; 190:704–705.
- 161 Kluger N, Giraud S, Coupier I, Avril MF, Dereure O, Guillot B, Richard S, Bessis D: Birt-Hogg-Dubé syndrome: clinical and genetic studies of 10 French families. Br J Dermatol 2010;162:527–537.
- 162 Onuki T, Goto Y, Kuramochi M, Inagaki M, Bhunchet E, Suzuki K, Tanaka R, Furuya M: Radiologically indeterminate pulmonary cysts in Birt-Hogg-Dubé syndrome. Ann Thorac Surg 2014;97:682–685.
- 163 Ayo DS, Aughenbaugh GL, Yi ES, Hand JL, Ryu JH: Cystic lung disease in Birt-Hogg-Dubé syndrome. Chest 2007;132:679–684.
- 164 Skolnik K, Tsai WH, Dornan K, Perrier R, Burrowes PW, Davidson WJ: Birt-Hogg-Dubé syndrome: a large single family cohort. Respir Res 2016;17:22.
- 165 Tobino K, Hirai T, Johkoh T, Kurihara M, Fujimoto K, Tomiyama N, Mishima M, Takahashi K, Seyama K: Differentiation between Birt-Hogg-Dubé syndrome and lymphangioleiomyomatosis: quantitative analysis of pulmonary cysts on computed tomography of the chest in 66 females. Eur J Radiol 2012;81:1340–1346.
- 166 Nishida C, Yatera K, Yamasaki K, Torii R, Kawanami Y, Kawanami T, Ishimoto H, Shibuya R, Takenaka M, Yamada S, Kasai T, Tanaka F, Mukae H: Possible familial case of Birt-Hogg-Dubé syndrome complicated with lung cancer: a possible link between these two disease entities. Respir Med 2015;109:923–925.
- 167 Benusiglio PR, Giraud S, Deveaux S, Méjean A, Correas JM, Joly D, Timsit MO, Ferlicot S, Verkarre V, Abadie C, Chauveau D, Le-roux D, Avril MF, Cordier JF, Richard S; French National Cancer Institute Inherited Predisposition to Kidney Cancer Network: Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multi-centre study. Orphanet J Rare Dis 2014;9:163.
- 168 Vincent A, Farley M, Chan E, James WD: Birt-Hogg-Dubé syndrome: a review of the literature and the differential diagnosis of firm facial papules. J Am Acad Dermatol 2003;49:698–705.
- 169 Welsch MJ, Krunic A, Medenica MM: Birt-Hogg-Dubé syndrome. Int J Dermatol 2005;44:668–673.
- 170 Tellechea O, Cardoso JC, Reis JP, Ramos L, Gameiro AR, Coutinho I, Baptista AP: Benign follicular tumors. An Bras Dermatol 2015;90: 780–796;quiz797–798.
- 171 Misago N, Kimura T, Narisawa Y: Fibrofolliculoma/trichodiscoma and fibrous papule (perifollicular fibroma/angiofibroma): a revaluation of the histopathological and immunohisto-chemical features. J Cutan Pathol 2009;36:943–951.
- 172 Luba MC, Bangs SA, Mohler AM, Stulberg DL: Common benign skin tumors. Am Fam Physician 2003; 67:729–738.
- 173 Pavlovich CP, Grubb RL 3rd, Hurley K, Glenn GM, Toro J, Schmidt LS, Torres-Cabala C, Merino MJ, Zbar B, Choyke P, Walther MM, Linehan WM: Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol 2005; 173:1482–1486.
- 174 Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ: Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 2002;26:1542–1552.
- 175 Gupta S, Kang HC, Ganeshan D, Morani A, Gautam R, Choyke PL, Kundra V: The ABCs of BHD: an in-depth review of Birt-Hogg-Dubé syndrome. AJR Am J Roentgenol 2017, Epub ahead of print.
- 176 Lindor NM, Kasperbauer J, Lewis JE, Pittelkow M: Birt-Hogg-Dubé syndrome presenting as multiple oncocytic parotid tumors. Hered Cancer Clin Pract 2012;10:13.
- 177 Maffé A, Toschi B, Circo G, Giachino D, Giglio S, Rizzo A, Carloni A, Polletti V, Tomassetti S, Ginardi C, Ungari S, Genuardi M: Constitutional FLCN mutations in patients with suspected Birt-Hogg-Dubé syndrome ascertained for non-cutaneous manifestations. Clin Genet 2011;79:345–354.
- 178 Gupta N, Sunwoo BY, Kotloff RM: Birt-Hogg-Dubé syndrome. Clin Chest Med 2016;37:475–486.
- 179 Nahorski MS, Lim DH, Martin L, Gille JJ, McKay K, Rehal PK, Ploeger HM, van Steensel M, Tomlinson IP, Latif F, Menko FH, Maher ER: Investigation of the Birt-Hogg-Dubé tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer. J Med Genet 2010;47:385–390.
- 180 Agarwal PP, Gross BH, Holloway BJ, Seely J, Stark P, Kazerooni EA: Thoracic CT findings in Birt-Hogg-Dubé syndrome. AJR Am J Roentgenol 2011;196:349–352.
- 181 Johannesma PC, Houweling AC, van Waesberghe JH, van Moorselaar RJ, Starink TM, Menko FH, Postmus PE: The pathogenesis of pneumothorax in Birt-Hogg-Dubé syndrome: a hypothesis. Respirology 2014;19:1248–1250.
- 182 Butnor KJ, Guinee DG Jr: Pleuropulmonary pathology of Birt-Hogg-Dubé syndrome. Am J Surg Pathol 2006;30:395–399.
- 183 Koga S, Furuya M, Takahashi Y, Tanaka R, Yamaguchi A, Yasufuku K, Hiroshima K, Kurihara M, Yoshino I, Aoki I, Nakatani Y: Lung cysts in Birt-Hogg-Dubé syndrome: histopathological characteristics and aberrant sequence repeats. Pathol Int 2009;59:720–728.
- 184 Kumasaka T, Hayashi T, Mitani K, Kataoka H, Kikkawa M, Tobino K, Kobayashi E, Gunji Y, Kunogi M,

- Kurihara M, Seyama K: Characterization of pulmonary cysts in Birt-Hogg-Dubé syndrome: histopathological and morphometric analysis of 229 pulmonary cysts from 50 unrelated patients. *Histopathology* 2014;65:100–110.
- 185 Johannesma PC, Reinhard R, Kon Y, Sriram JD, Smit HJ, van Moorselaar RJ, Menko FH, Postmus PE; Amsterdam BHD Working Group: Prevalence of Birt-Hogg-Dubé syndrome in patients with apparently primary spontaneous pneumothorax. *Eur Respir J* 2015;45:1191–1194.
- 186 Stamatakis L, Metwalli AR, Middleton LA, Linehan WM: Diagnosis and management of BHD-associated kidney cancer. *Fam Cancer* 2013;12:397–402.
- 187 Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM: Small (c; or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. *Radiology* 1996;198:785–788.
- 188 Schmidt LS, Linehan WM: Clinical features, genetics and potential therapeutic approaches for Birt-Hogg-Dubé syndrome. *Expert Opin Orphan Drugs* 2015;3:15–29.
- 189 Nakamura M, Yao M, Sano F, Sakata R, Tatenuma T, Makiyama K, Nakaigawa N, Kubota Y: A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents (in Japanese). *Hinyokika Kiyo* 2013;59:503–506.
- 190 Gambichler T, Wolter M, Altmeyer P, Hoffman K: Treatment of Birt-Hogg-Dubé syndrome with erbium: YAG laser. *J Am Acad Dermatol* 2000;43:856–858.
- 191 Jacob CI, Dover JS: Birt-Hogg-Dubé syndrome: treatment of cutaneous manifestations with laser skin resurfacing. *Arch Dermatol* 2001;137:98–99.
- 192 Al-Daraji WI, Al-Razag ZA, Craven N, Twaij Z: Multiple hereditary facial papules. *Clin Exp Dermatol* 2005;30:309–310.
- 193 Felton SJ, Madan V: Facial and upper body papules in a patient with a family history of recurrent pneumothorax. *JAMA* 2012;308:2622–2623.
- 194 Gijzen LM, Vernooij M, Martens H, Oduber CE, Henquet CJ, Starink TM, Prins MH, Menko FH, Nelemans PJ, van Steensel MA: Topical rapamycin as a treatment for fibrofolliculomas in Birt-Hogg-Dubé syndrome: a double-blind placebo-controlled randomized split-face trial. *PLoS One* 2014;9:e99071.